EpiEndo Pharmaceuticals is developing glasmacinal, a non-antibiotic macrolide designed to enhance host defense responses and reduce inflammation in patients with chronic respiratory diseases, particularly COPD. This oral treatment aims to decrease the frequency and severity of exacerbations while minimizing the risk of antimicrobial resistance associated with traditional therapies.
Funding
Funding not disclosed
Founders
Product
Problem
Chronic obstructive pulmonary disease (COPD) is a leading cause of death globally, characterized by irreversible airflow obstruction and frequent exacerbations. These exacerbations, often triggered by viral or bacterial infections and airborne irritants, significantly impact patients' quality of life and contribute to a substantial economic burden. Current treatments primarily involve bronchodilators and corticosteroids, leaving a need for therapies that address the underlying host defense mechanisms without promoting antimicrobial resistance.
Solution
EpiEndo Pharmaceuticals is developing glasmacinal, a first-in-class, non-antibiotic macrolide, to address the unmet needs of COPD patients. Glasmacinal is designed to enhance the host defense response and reduce inflammation in the respiratory system, thereby decreasing the frequency, severity, and duration of COPD exacerbations. This oral treatment aims to provide a long-term therapeutic option without the risk of antimicrobial resistance associated with traditional macrolides. By improving the body's natural defenses against pathogens and irritants, glasmacinal has the potential to reduce hospitalizations and improve the overall quality of life for individuals suffering from chronic respiratory diseases. EpiEndo's Barriolides™ represent a new class of oral drugs with the potential to transform the treatment landscape for COPD and other chronic respiratory conditions.
Target Audience
The primary target audience includes patients diagnosed with COPD and other chronic respiratory diseases, as well as healthcare providers specializing in pulmonology and respiratory care.
Features
- Oral administration for convenient, systemic delivery
- Non-antibiotic macrolide structure designed to avoid antimicrobial resistance
- Enhancement of host defense mechanisms to combat respiratory infections
- Anti-inflammatory properties to reduce airway inflammation
- Potential to decrease the frequency, severity, and duration of COPD exacerbations
- Reduction in hospitalizations associated with COPD exacerbations
- First-in-class Barriolide™ mechanism of action